Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy - A Phase II Trial

NCT02560337 is registered in ClinicalTrials.gov with Vejle Hospital as lead sponsor.

NCT NCT02560337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02560337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy - A Phase II Trial
Lead sponsor
Vejle Hospital
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2015
Completion date
June 1, 2019
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer